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INVESTIGATING THE NEUROPILIN 2/SEMAPHORIN 3F PATHWAY IN 
MELANOCYTES, MELANOMA, AND ASSOCIATED THERAPIES 
COLIN M. RIVET 
ABSTRACT 
Introduction: Melanoma is the most deadly skin cancer with mortality dependent 
on the extent and location of metastases. Lymphatic metastasis occurs early in 
melanoma, and tumor-associated lymphatic vessel area correlates with 
melanoma progression. Recently, the discovery of checkpoint inhibitors has 
drastically changed the treatment strategy and survival rates in melanoma. 
Neuropilin-2 (NRP2) is a potential common target in melanoma cells, tumor-
associated lymphatic endothelial cells (LECs) and tumor-infiltrating lymphocytes 
(TILs). NRP2 is a cell surface receptor with competing stimulatory ligands 
(VEGF-A/-C) and inhibitory ligands (SEMA3F/G).   
Aim: The goal of this study was to investigate the role of NRP2 in both 
melanoma cells and the melanoma microenvironment (LECs, TILs) and to 
examine the effect of semaphorin 3F (SEMA3F) on the tumor cells as well as an 
immune modulator. 
Results: Mouse and human melanocytes expressed NRP2 but not other 
vascular endothelial growth factor (VEGF) receptor tyrosine kinases in vitro and 
in vivo. NRP2 protein expression, as analyzed by immunohistochemistry, was 
upregulated in human metastatic melanoma sections. Treatment of melanoma 






kinase B (AKT) but did not inhibit cell viability. SEMA3F also increased 
programmed cell death-ligand 1 (PD-L1) expression in melanoma. Syngeneic 
B16F10 melanoma did not grow in global NRP2 knockout (KO) mice but did grow 
in wild-type mice. In addition, mice inoculated with B16F10 were treated with 
SEMA3F or phosphate-buffered saline (PBS) by mini-osmotic pumps. Resulting 
tumors were analyzed histologically for microvessel density and presence of TILs 
(number and subtype).  
Conclusions: Expression of NRP2 protein positively correlated with melanoma 
progression in human patient samples. NRP2 functions differently in melanoma 
tumor cells than in host stromal cells (endothelial cells [ECs], LECs). In 
melanoma, NRP2 is not a VEGF receptor but responds to the ligand, SEMA3F. 
Alternately, NRP2 appears to be an important VEGF-A/-C co-receptor in tumor-
associated angiogenesis and lymphangiogenesis, as demonstrated in the NRP2 
transgenic mice studies. SEMA3F inhibited tumor cell migration but increased 
PD-L1 expression. Systemic treatment with purified SEMA3F protein in 
melanoma preclinical trials inhibited melanoma growth and microvessel density. 
Taken together, these results suggest that exploiting the NRP2/SEMA3F 
signaling axis may be a novel treatment strategy to be used in combination with 
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 Neuropilin (NRP) is a transmembrane glycoprotein with forms in humans 
and mice, neuropilin-1 (human: NRP1; mouse: Nrp1) and neuropilin-2 (human: 
NRP2; mouse: Nrp2). As shown in Figure 1, NRP has the ability to bind two 
ligands, vascular endothelial growth factor (VEGF), and a family of proteins 
called class 3 semaphorins (human: SEMA, mouse: Sema) (Goodman, Kolodkin, 
Luo, Püschel, & Raper, 1999). Both ligands have the same affinity to bind NRP; 
thus they follow a competitive binding model, and whichever one is in greater 
excess is the one that binds NRP. The structure of NRP consists of an 
extracellular region with a1a2, b1b2, and c domains. The c domain is responsible 
for the dimerization with either vascular endothelial growth factor receptor 
(VEGFR) for VEGF or plexin for SEMA (Bielenberg, Pettaway, Takashima, & 
Klagsbrun, 2006). Binding of VEGF or SEMA to NRP alone is not sufficient to 
initiate an intracellular signaling pathway (Favier et al., 2006). The intracellular 
domain is composed of 40 amino acids ending in a SEA (sea urchin sperm 
protein, enterokinase, and agrin) motif that binds neuropilin interacting protein 
(NIP); however, this motif has no known signaling function. In addition to the 
transmembrane NRPs, there also exists a soluble form. When the soluble form is 
compared with the transmembrane form, it is noticed that the soluble form lacks 
the c domain which is present in the transmembrane extracellular component 
and the transmembrane and intracellular domains (Bielenberg et al., 2006). 
	  
2 
Although NRP1 and NRP2 share 45% gene homology, they are found on 
different chromosomes, with NRP1 on chromosome 10 and NRP2 on 
chromosome 2 (Rossignol, Gagnon, & Klagsbrun, 2000). The two NRPs have the 
same structure even though they differ in location of expression (Bielenberg et 
al., 2006). In the vasculature, NRP1 is expressed on arterial endothelial cells 
(ECs), whereas NRP2 is found on both venous and lymphatic ECs (Bielenberg et 
al., 2004). 
 
Figure 1. Neuropilin-1/-2 and its ligands, VEGF and SEMA. The figure shows 
the transmembrane receptor NRP and two of its main ligands, VEGF and SEMA. 
The diagram displays the specific binding locations for each ligand, along with 
the appropriate coreceptor for each ligand. NRP = neuropilin (human); SEMA = 
semaphoring (human); VEGF = vascular endothelial growth factor; VEGFR = 
vascular endothelial growth factor receptor. Unpublished; contributed by (D. 
Bielenberg, 2018). 
 
Vascular Endothelial Growth Factor 
 Another important ligand of NRP is VEGF. This signaling protein was 
originally discovered as vascular permeability factor (VPF) by Dr. Harold Dvorak 
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in 1983 (Senger et al., 1983). VEGF is known to be a major governor of both 
physiological and pathological angiogenesis, and it has been shown to promote 
EC proliferation, migration, survival, and permeability (Djordjevic & Driscoll, 
2013) 
 Later on, it was discovered that VEGF is a family of six soluble 
glycoproteins, including the following: VEGF, later named vascular endothelial 
growth factor-A (VEGF-A), vascular endothelial growth factor-B (VEGF-B), 
vascular endothelial growth factor-C (VEGF-C), vascular endothelial growth 
factor-D (VEGF-D), vascular endothelial growth factor-E (VEGF-E), and placenta 
growth factor (PGF) (Veikkola & Alitalo, 1999). These differing forms of VEGF 
signal through receptor tyrosine kinases (RTKs), specifically VEGFR (Djordjevic 
& Driscoll, 2013). Upon binding of VEGF to VEGFR, the receptor is induced to 
dimerize and then autophosphorylate the cytoplasmic domain of the adjacent 
receptor. To date, there are three known subtypes of VEGFR: VEGFR1 (FLT-1), 
VEGFR2 (KDR), and VEGFR3 (FLT-4). In adult tissue, each VEGFR has 
specialized locations. VEGFR1 and VEGFR2 are expressed on vascular ECs, 
and VEGFR3 is mainly found on lymphatic ECs. Because there are several 
different forms of both VEGF and VEGFR, certain VEGFs bind certain VEGFRs 
with specific affinities. It has been demonstrated that VEGFR1 binds VEGF-A, 
VEGF-B, and PGF; VEGFR2 binds VEGF-A, VEGF-C, VEGF-D, and VEGF-E; 
and finally VEGFR3 binds VEGF-C and VEGF-D (Veikkola & Alitalo, 1999). 
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 In addition to the discovery of VEGFRs being receptors for VEGF, it was 
also discovered that NRP1 was a coreceptor for VEGF by Dr. Michael Klagsbrun 
in 1998 (Soker, Takashima, Miao, Neufeld, & Klagsbrun, 1998). It was later 
elucidated that VEGF-A isoform 165 binds both NRP1 and NPR2 by its exon 7 at 
the b1b2 domain of NRP1/2 prior to dimerization with VEGFR. An overall 
breakdown of the specific VEGF isoform-NRP binding is as follows: NRP1 binds 
VEGF-A isoform 165, VEGF-B, VEGF-E, and PGF2; and NRP2 binds VEGF-A 
isoforms 145 and 165 and VEGF-C (Bielenberg et al., 2006).  
 Because VEGF appears to have two different receptors, it is appropriate 
to ask the questions “What is the difference between them?” and “Can they work 
together?” As previously stated, VEGF has the ability to bind either VEGFR or 
NRP individually. When VEGF binds NRP and does not dimerize with a VEGFR, 
there is an absence of signaling that takes place. This is in contrast to when 
VEGF binds VEGFR, resulting in dimerization with another VEGFR and 
subsequent signaling. Also, when a VEGF binds an NRP and that NRP dimerizes 
with a VEGFR, a signal is produced in the same manner as seen with the binding 
and dimerization of VEGFR alone. However, the difference is observed when the 
VEGF binds NRP and then dimerizes with VEGFR. This type of binding leads to 
an enhanced phosphorylation of the VEGFR and the production of an amplified 
signal. In addition, the VEGFR is recycled back to the cell surface, becoming 





 There are seven classes of SEMAs; however, only one of these classes, 
SEMA3, is secreted. Within the class 3 SEMA, there are six different proteins: 
SEMA3A, SEMA3B, SEMA3C, SEMA3D, SEMA3E, and SEMA3F. It is this class 
of secreted SEMA that binds NRP1 and NRP2. NRP1 binds SEMA3A, NRP2 
binds SEMA3F, and both NRPs bind SEMA3B. The binding takes place at both 
the a1a2 and b1b2 domains of the NRP receptor (Bielenberg et al., 2006).  
 SEMA is known to function as a repellent when guiding the patterning of 
neurons (Chen, He, Bagri, & Tessier-Lavigne, 1998). The NRP/SEMA interaction 
is often associated with an inhibitory, or repellent, effect. In order for SEMA to 
participate in signaling, binding of NRP alone is not sufficient (Bielenberg et al., 
2004). Besides binding NRP, SEMA must then complex with plexin. When 
SEMA3 binds NRP2 and complexes with plexin A1, several outcomes can result 
from the structure (Nakayama et al., 2015). Such outcomes include SEMA3A 
causing the depolymerization of F-actin, which acts to inhibit EC motility and 
proliferation, and SEMA3F inhibiting angiogenesis. In addition, SEMA3A and 
SEMA3F have been proposed to be tumor inhibitors. This led to the study of 
SEMA3F and its possible ability to affect cancer metastasis because of the fact 
that SEMA3F had been shown to be downregulated in cancers with a high 
metastatic potential. The resulting study found that when SEMA3F was 
transfected into cancer cells, their metastatic potential and phenotype were 
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moved toward decreased metastasis and a benign phenotype (Bielenberg et al., 
2004). 
Angiogenesis 
 Angiogenesis is defined as the formation of a new blood vessel from an 
existing one, and it continues throughout all stages of one’s life. This process is 
present in a physiologic manner as well as a pathological one because no 
metabolically active tissue can survive without being only micrometers away from 
a capillary. The capillary provides the oxygen and nutrients that the tissue 
requires. This angiogenic process is a dynamic and fluid one. In the same 
manner that a bone responds to stimuli and stress, blood vessels respond to 
ever-changing tissue demands in order to maintain the supply in accordance to 
the demand. Angiogenesis is by no means the only type of vascular growth. 
Other types include vasculogenesis, venogenesis, arteriogenesis, and 
lymphangiogenesis (Adair & Montani, 2010). 
 There are two forms of angiogenesis, sprouting and intussusceptive, with 
both types taking place in all tissues. Sprouting angiogenesis, as its name 
suggests, is when branches of ECs split off the main vessel and start migrating 
along a chemogradient toward an angiogenic signal. This type of angiogenesis 
occurs in response to hypoxic, or low-oxygen, conditions within tissues. The 
tissue responds to the oxygen depletion by secreting a proangiogenic signal, 
VEGF-A. This in turn acts on special ECs called tip cells, causing them to branch 
off the existing vessel and begin migrating through the extracellular matrix (ECM) 
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in the direction of the stimulus (Figure 2). These tip cells secrete large amounts 
of proteolytic enzymes in order to carve out a path through the ECM. In addition, 
the tip cells contain VEGFR2, which allows the tip cells to sense changes in and 
follow the VEGF-A chemogradient. The ECs that follow the tip cells are named 
stalk cells, and they proliferate, forming the lumen as the migration occurs. Once 
the tip cells come into contact with other migrating tip cells, they fuse together 
into an uninterrupted lumen through which blood can flow. However, the vessel is 
not 100 percent complete because it still needs to stabilize and mature. This 
process is done by pericytes and ECM in combination with the sheer stress that 
the blood flow exerts on the vessel wall. With the return of oxygen and 
metabolites to the tissue, the hypoxic environment is remedied, and the 




Figure 2. VEGF chemogradient effects on sprouting angiogenesis. The 
VEGFR2 on the tip cells sense the VEGF chemogradient and begin to migrate 
and proliferate in that direction. VEGF = vascular endothelial growth factor; 
VEGFR2 = vascular endothelial growth factor receptor. Unpublished; contributed 
by (D. Bielenberg, 2018). 
 
 Because of its recent discovery, far less is known about intussusceptive 
angiogenesis than its counterpart, sprouting angiogenesis. Intussusceptive 
angiogenesis occurs when the vessel wall penetrates into the lumen, splitting the 
vessel in half. Compared with sprouting angiogenesis, this method is faster 
because it only reorganizes ECs and is not dependent on EC proliferation and 
migration. However, like sprouting angiogenesis, intussusceptive angiogenesis 
occurs throughout one’s lifetime, although it is believed to occur more 
prominently in embryos (Adair & Montani, 2010).  
 The first step in the intussusceptive angiogenesis process is the formation 
of transcapillary tissue pillars (Figure 3). These pillars are areas of ECM covered 
by ECs that form during a four-phase process. In the first phase, opposing 
capillary walls establish what is called a “zone of contact.” In the second phase, 
the inter-endothelial cells reorganize their junctions in order to confirm the zone 
of contact, and the EC layer is centrally perforated on both sides. During the third 
phase, pericytes and myofibroblasts enter the interstitial pillar core and produce 
collagen fibrils. In the final phase, the pillars increase in circumference but do not 
experience any additional changes in their fundamental structure (Djonov, Baum, 




Figure 3. Four phases of transcapillary tissue pillar formation. The diagram 
shows a visual representation of each phase of the pillar formation. Phase one is 
characterized by the establishment of a zone of contact between the opposing 
walls of the capillary. In phase two the inter-EC junctions reorganize. Phase three 
is where the interstitial pillar core is formed. The final phase, 4, the pillars 
increase in girth.  BM = basement membrane; Co = collagen fibrils; EC = 




 Lymphatics, in combination with blood vessels, make up the human 
circulatory system. During development in utero, lymphatics sprout from existing 
veins; however, this is where much of the similarity ends between lymphatics and 
blood vessels. Unlike blood vessels which form a closed system, the lymphatic 
system is an open system. The lymphatic capillaries take up both fluid and cells, 
and these components are then filtered through one or more lymph nodes before 
being returned to the venous system. The lymphatic vessels differ in both 
structure and function from the rest of the vasculature. Large numbers of the 
lymphatic capillaries are without a basement membrane or pericytes, and this 
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condition is beneficial to cells entering the lymphatic capillaries. In addition, there 
are anchoring filaments that connect to button junctions between lymphatic ECs 
(LECs). When the interstitial fluid pressure rises, these filaments act to open 
small gaps at these button junctions. This action serves to protect the tissue from 
harmful edema by aiding in fluid drainage from the tissue while allowing immune 
cells access to the lymph node. Although all these features are important to the 
normal functioning of the tissue and vasculature, they also allow tumor cells to 
penetrate the lymphatic vessels and go to the lymph nodes, an important step in 
metastasis (Bielenberg & Zetter, 2015).  
 Tumor lymphangiogenesis is similar to tumor angiogenesis in that they 
both increase microvascular density, depend on growth factors, and result in 
porous and incomplete capillaries and vessels. For all their similarities, there are 
also differences. For example, unlike tumor angiogenesis which invades the 
tumor, tumor lymphangiogenesis tends to occur adjacent to the tumor and rarely 
invades. In addition, the already present lymphatic vessels, which surround the 
tumor, expand (Bielenberg & Zetter, 2015).  
 The major governing growth factor in tumor lymphangiogenesis is the 
upregulation of VEGF-C, and the subsequent increase in surrounding and 
invading tumor lymphangiogenesis correlates with an increase in lymph node 
metastases (Skobe et al., 2001). However, invading lymphangiogenesis is not 
necessary for lymph node metastasis. If VEGF-C is eliminated, the invading 
lymphangiogenesis is decreased, but the overall lymph node metastases are 
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maintained when compared with VEGF-C present models (Wong et al., 2005). 
As figure 4 demonstrates lymph node metastases are capable of remaining in the 
lymph node or moving into a blood vessel and then to an organ. Overall, the 
presence of lymph node metastases are correlated with both an increased 
incidence of distant organ metastasis and a poorer prognosis (Bielenberg & 
Zetter, 2015). 
 
Figure 4. Routes of metastases through the blood and lymphatic 
vasculature. Metastases can travel to distant organs via both lymphatic and 
blood vasculature methods. Within the lymphatic route once metastases have 
entered into the lymph node they have the ability to stay within the node or to exit 




 The skin is the largest organ in the human body and is composed of three 
layers: the epidermis, the dermis, and the subcutaneous (listed from superficial to 
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deep). Within the epidermis, residing in the basal layer, are melanocytes. These 
cells produce a protein called melanin that gives color to the skin, hair, and eyes. 
Melanin also helps to carry out one of the most important functions of the skin: 
protection against ultraviolet (UV) radiation. This UV radiation results in damage 
within the DNA of the cells of the skin, and this damage has the ability to change 
an otherwise normal cell into a cancerous one (Grether-Beck, Marini, Jaenicke, & 
Krutmann, 2014). 
 Melanocytes originate from neural crest cells (NCCs) that form from the 
neural ectoderm, an ectoderm different from the ectoderm which produces the 
rest of the skin. The fact that melanocytes originate from NCCs is important when 
differentiating between pigment-producing cells. There are other cells, such as 
adipocytes and pigmented epithelium of retina, that produce melanin; however, 
these cells differ in their embryonic origin from melanocytes. NCCs are often 
divided into four subpopulations based on regional location (cranial, vagal, trunk, 
and sacral), but it is the trunk NCCs which give rise to epidermal melanocytes. 
These trunk NCCs can be divided further into ventral (between the neural tube 
and somites) and dorsal (between the surface ectoderm and somites).  
 Conventionally, the dorso-laterally migrating NCCs are the cells that serve 
as the main source for epidermal melanocytes. These melanocytes migrate from 
their original location to their final one. This migration takes place while they are 
still NCCs and melanoblasts. Their migration is partially directed by SEMA 
because NCCs express NRP1/2. Melanocytes begin migrating while still NCCs, 
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but it is during this migration that they become melanoblasts and multiply. Once 
the melanoblasts reach their final destination, which can be the epidermis, the 
iris, the bulb of hair follicles, or some less well-known locations, they terminally 
differentiate into melanocytes (Cichorek, Wachulska, Stasiewicz, & Tymińska, 
2013). 
Cancer 
 Cancer results when there are a multitude of changes that occur to the 
genome of a normal cell, transforming it into a cancerous cell. There are six 
acquired changes that are characteristic of cancer, and these changes must 
occur in the following order to have a malignancy: evading apoptosis, self-
sufficiency in growth signals, insensitivity to anti-growth signals, sustained 
angiogenesis, limitless replicative potential, and tissue invasion and metastasis 
(Figure 5). Although these changes can happen in any order, they all need to 
happen in the specified order to have a malignant tumor. However, these 
changes do not need to take place within a single cell, but rather as an 




Figure 5. Necessary acquired changes for tumor malignancy. The diagram 
shows the six necessary changes that must occur for a tumor to become 
malignant. Not every cell within the tumor must have these changes, but the 
tumor as a single entity must have all of these changes. Adapted from (Hanahan 
& Weinberg, 2000). 
 
 Metastasis is one of the six characteristics of malignancy; however, it is 
often the metastasis that results in death and not the primary tumor itself (Fidler, 
2003). One of the most important concepts when looking at metastasis, as 
originally discussed by Dr. Stephen Paget (1889), is the notion of “seed and soil.” 
He concluded that the probability and location of metastasis was not random but 
instead was dependent upon the specific tumor cell searching for a specific 
organ for which it had an affinity. If the cell did not find the proper organ, then 
metastasis did not occur (Paget, 1889). This was again noted in 1951 by Coman, 
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deLong and McCutcheon who observed that when tumor cells were injected into 
the intravascular, metastasis resulted in some but not all organs. However, their 
study also illuminated the location where tumor cells could arrest. If the tumor 
cells were successful in proliferating in a specific organ, the cells arrested in the 
capillaries compared with the arterioles in organs where metastasis was rare 
(Coman, deLong, & McCutcheon, 1951) This helped to illuminate the mechanical 
aspect of metastasis. Through tumor cell-labeling techniques (labeling tumor 
cells with 125I-5-iodo-2ꞌ-deoxyuridine), it was observed that less than a day after 
tumor cells entered the circulation, only 0.1% remained viable, and of these 
viable cells, less than 0.01% were able to survive and generate metastasis 
(Fidler, 1970). Thus it was later discovered that metastasis is a selective process 
(Fidler, 2003).   
 For a tumor cell to successfully metastasize, it must go through a number 




Figure 6. Metastatic process for a tumor cell. The diagram shows the 
necessary steps that a tumor must undergo in order to successfully metastasize. 
Taken from (Fidler, Kumar, Bielenberg, & Ellis, 1998).  
 
At any point in this cascade, failure can occur, which results in the cell failing to 
successfully metastasize.  
 Today the “seed and soil” hypothesis is defined by three principles: 
primary neoplasms are made up of both tumor and host cells, the metastatic 
process selects for cells that are successful in all steps required for metastasis, 







 Skin cancer is one of the most common types of cancer. Although most 
skin cancers are easily curable, not all types are created equal. The most 
dangerous and deadly form of skin cancer is melanoma. Melanoma is the cancer 
that occurs within the melanocytes, the cells that provide the pigmentation of the 
skin, hair, and eyes. Melanocytes are also found in other areas of the body, such 
as the gastrointestinal tract and the ears. Because of the diverse locations within 
the human body where melanocytes are found, there are both UV-dependent 
and non-UV-dependent melanomas (McCourt, Dolan, & Gormley, 2014; 
Yamaguchi & Hearing, 2014). 
 The progression from melanocyte to malignant melanoma is not just a 
two-step pathway but instead involves a multitude of intermediate stages. The 
path from the original, normal functioning melanocyte begins with the formation 
of a naevus. A naevus is the result of a concentrated, benign proliferation of 
melanocytes. The individual naevus does not usually lead to melanoma; 
however, when there is an increase in number, they can contribute to melanoma. 
These naevi contain a BRAF mutation which serves as the initiating event for 
proliferation. The next step on the pathway is the formation of dysplastic naevi. 
This form of naevi contains both benign and malignant features. They have the 
ability to come from already existing, common naevi or to form de novo if they 
are associated with hereditary risk. What follows is an actual melanoma 
diagnosis called melanoma in situ. This stage is recognizable by the enlarged 
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nuclei within an irregular patterned, proliferating group of melanocytes. The in 
situ portion is an important component because it means that the melanoma has 
only undergone radial growth and not vertical growth. Thus the melanoma has 
not broken through the basement membrane and is still confined to the epidermis 
where it is easy to remove and completely curative. Once a melanoma in no 
longer strictly confined to the epidermis but has entered the dermis and 
submucosal tissue, it is defined as an invasive melanoma. This shift to an 
invasive melanoma is associated with the acquisition of a driver mutation that 
serves to turn on the mitogen-activated protein kinase (MAPK) pathway. 
Metastatic melanoma is the final step in the melanocyte-to-malignant melanoma 
pathway. Metastatic melanoma is reached once malignant cells have traveled 
beyond their original location. This is the most dangerous kind of melanoma 
because it begins to affect other organs, and as previously stated, most cancer-
related deaths are due to the metastasis and not the primary tumors (Shain & 
Bastian, 2016). 
 As Figure 7 shows, melanomas express high amounts of NRP2. This 
occurs in part because melanoma is a cancer that is derived from a neural origin 
(melanocytes are NCC-derived) (Rossi et al., 2014). The NRP2 plays an 
important role in both tumor angiogenesis and tumor lymphangiogenesis; 
therefore, it is not surprising that melanomas are known to have high 
microvascular density (Bielenberg & Zetter, 2015). This increased tumor 
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angiogenesis and tumor lymphangiogenesis contribute to increased metastatic 
potential and poorer prognosis (Rossi et al., 2014).  
 
Figure 7. NRP1/2 expression in melanoma. This image demonstrates that 
when melanomas are compared with carcinomas, melanomas express a higher 
amount of NRP2. In fact, the melanoma NRP2 expression is most similar to the 
glioblastoma (U87MG). Pae NRP2 (NRP2 transfected positive control), HUVEC 
(human umbilical vein endothelial cell), A375SM (human melanoma), A2058 
(human melanoma), U87MG (human glioblastoma), PC3MLN4 (human prostate 
carcinoma), Du145LN2 (human prostate carcinoma metastases site, brain), 
MCF7MFP1 (human breast carcinoma), Aspc1 (human pancreas 
adenocarcinoma), BxPc3 (human pancreas adenocarcinoma), Pae NRP1 (NRP1 
transfected positive control). Unpublished; contributed by (D. Bielenberg, 2018). 
 
Immunotherapy 
 Prior to the development and implementation of immune checkpoint 
inhibitors in the clinic, patients with metastatic melanoma had a very grim 
prognosis. However, with the discovery and use of immunotherapeutic agents, 
such as anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and anti-
programmed cell death protein 1 (PD-1), patient prognoses and survival rates 
have increased. The antibodies serve to “super charge” the patient’s immune 
system and unleash it on the cancer (Buchbinder & Desai, 2016). 
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 In order to understand the mechanisms behind these treatments, one 
must first understand the function in a normal physiologic sense. The immune 
system is classically divided into two subpopulations, the innate and the adaptive 
immune systems. The innate immune system functions as a nonspecific immune 
response to a pathogen while simultaneously stimulating the specific immune 
response of the adaptive immune system (Alberts et al., 2002). In addition to 
fighting off pathogens, the immune system must make sure that it does not 
engage in “friendly fire” by attacking itself; that is, it must be able to recognize 
self from nonself. One way to help with this is that the cells of the adaptive 
immune system, T and B cells, must be activated. The activation of T cells 
occurs through a “two hit theory.” The first binding occurs between a T-cell 
receptor (TCR) and an antigen that is being displayed on a class II major 
histocompatibility complex (MHC). This provides the specificity. Once this binding 
has successfully occurred, a costimulatory molecule on the antigen-presenting 
cell (APC), such as protein B7-1 or B7-2, must bind the cluster of differentiation 
28 (CD28) protein on the T cell. If all of this happens, then the T cell is activated. 
If only the TCR:MHC interaction occurs, then the T cell is not activated, and it 
becomes anergic. In addition to the above stated cell surface proteins there are 
other surface proteins present on the surrounding cells, the APCs and the T 
cells. Some of these molecules make up checkpoints that function to control the 
immune response and ensure that it does not result in autoimmunity. Some of 
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the more well-known checkpoint molecules are CTLA-4 and PD-1 (Buchbinder & 
Desai, 2016).  
 These two inhibitory checkpoint molecules function at different stages 
during an immune response. CTLA-4-mediated action (Figure 8) generally occurs 
in the priming phase of naïve T cells in the lymph node and functions to prevent 
any autoreactive T cells from continuing (also known as central tolerance). 
CTLA-4 is found on the cell surface of T cells and, like CD28, binds B7 ligands 
but with a greater affinity. When CTLA-4 successfully binds a B7 ligand, the 
interaction eliminates one B7 ligand molecule that is available to bind CD28 and 
thus reduces the possibility that a costimulatory stimulus is sent. If a greater 
relative amount of B7 ligand is bound by CTLA-4 compared with CD28, then no 
costimulatory signal is sent, and the T cell is not activated (Chambers, Kuhns, 
Egen, & Allison, 2001). CTLA-4 is also subject to regulation. If stimulatory signals 
from B7:CD28 binding are being sent, then CTLA-4 expression on the cell 
surface is increased by means of the exocytosis of CTLA-4 filled vesicles from 
within the cell. In addition to inhibiting the activation of T cells and preventing 
autoimmunity, CTLA-4 plays an important role in regulating the function of 
effector T cells through its constitutive expression on the surface of regulatory T 
cells (T regs) (Takahashi et al., 2000). These T regs serve to dampen and 
reduce the immune response. It is thought that they accomplish this function with 
their large relative amount of cell surface CTLA-4 binding of B7 ligands on APCs, 
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thus reducing the amount available for CD28 binding and activation (Wing et al., 
2008).  
 
Figure 8. T cell regulation by CTLA-4. The diagram shows that when there is 
MHC:TCR binding in addition to a larger relative amount of B7:CD28 binding, T 
cell activation occurs. At the same time, if there is a larger relative amount of 
B7:CTLA-4 binding, then T cell inhibition occurs. CTLA-4 = cytotoxic T-
lymphocyte-associated antigen-4; TCR = T-cell receptor; MHC = major 
histocompadibility complex. Adapted from (Buchbinder & Desai, 2016).  
 
 Another inhibitory checkpoint molecule is PD-1. Its ligands are 
programmed cell death-ligand 1 (PD-L1) and programmed cell death-ligand 2 
(PD-L2). When PD-1 binds one of its ligands, the result is T cell inhibition and 
inactivation. The process behind the PD-1 inhibition is due to its ability to prevent 
the phosphorylation of the TCR downstream signaling targets (Buchbinder & 
Desai, 2016). Increased expression of PD-1 is seen in T cell exhaustion, which 
often occurs during prolonged, chronic infections and in cancer. This increased 
PD-1 expression results in T cell dysfunction through increased inhibitory 
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receptors and poor effector function (Wherry, 2011). Although PD-1 and CTLA-4 
are similar in that they both result in the dampening and control of the immune 
response, PD-1 differs from CTLA-4 in that the ligands for PD-1 are expressed 
not only on APCs but also on other immune cells, nonimmune cells, and tumor 
cells. In addition, PD-1 is a key player in peripheral tolerance and not central 
tolerance, so it controls T cells that have already made it through the selection 
phase and are currently effector T cells fighting infection or cancer (they are in 
the periphery at the location of interest). Furthermore, whereas CTLA-4 is 
expressed solely on T cells, PD-1 is found not only on activated T cells but also 
on B cells and myeloid cells (Buchbinder & Desai, 2016). PD-L1 is also found on 
tumor cells, and with this expression, tumor cells are frequently able to evade the 
immune system, leading to possibly poorer prognosis. However, the presence of 
PD-L1 does not represent a clear-cut prognosticator but instead is quite variable. 
In some cancers, such as melanoma, PD-L1 correlates with a poorer prognosis, 
whereas in other cancers, it correlates with an improved prognosis (Frydenlund & 
Mahalingam, 2017; Wang, Liu, & Liu, 2017). 
 The treatments with anti-CTLA-4 and anti-PD-1 use monoclonal 
antibodies that bind the checkpoint molecules and prevent their interactions with 
their respective ligands (Figure 9). Though both treatments function to uncloak 
the tumor cells and remove the brakes from the immune system, they do so in 
differing manners. Treatment with anti-CTLA-4 acts during the priming phase and 
serves to increase T cell activation, proliferation, and overall survival and to 
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reduce the effectiveness of T regs modulating the immune response. Treatment 
with anti-PD-1 operates in the periphery to return T cells to their effector state 
that had been either turned off or exhausted. Currently in the clinic, some 
patients are receiving both anti-CTLA-4 and anti-PD-1 treatments. These 
treatments have shown a synergistic effect because of their differences in 
mechanism, location, and timing of action (Buchbinder & Desai, 2016). 
 
Figure 9. Anti-CTLA-4 and anti-PD-1 treatment mechanisms. The diagram 
shows the end result of utilizing anti-CTLA-4 or anti-PD-1 antibodies in cancer 
treatments. CTLA-4 = cytotoxic T-lymphocyte-associated antigen-4; PD-1 = 








For the culturing of most cells in vitro, completed medium was prepared 
consisting of 10% fetal bovine serum (FBS) purchased from Genesee and 1% 
glutamine penicillin-streptomycin (GPS) purchased from Gibco. Different cell 
lines required different types of medium to be used. Table 1 indicates the 
medium used for each cell line that was cultured. Dulbecco’s modified Eagle 
medium (DMEM) and Roswell Park Memorial Institute 1640 (RPMI-1640) were 
purchased from HyClone. Medium 199 was purchased from Lonza and mixed 
with human melanocyte growth supplement (HMGS, ThermoFischer) to create 
growth media for primary melanocytes. Endothelial basal medium (EBM) and the 
EC growth supplement bullet kit were purchased from Lonza and mixed to create 
endothelial growth media (EGM2). Trypsin ethylenediaminetetraacetic acid 
(EDTA) 0.05% was used to detach cells and was purchased from Sigma. 
Nonessential amino acids (NEAA) and sodium pyruvate (C3H3NaO3) were 








Table 1. List of Cell Lines and Primary Cells Used for In Vitro Experiments 
and In Vivo Animal Modelsa 
Cell Line Description Media FBS GPS NEAA C3H3NaO3 %CO2 
B16F10 Murine 
melanoma 
DMEM 10% 1% NA NA 5% 
MC-38 Murine colon 
adenocarcinoma 





DMEM 10% 1% NA NA 10% 
WT-4 Murine oral 
carcinoma 
DMEM 10% 1% NA NA 5% 




10% 1% NA NA 5% 
Skin EC Primary murine 
endothelial cell 




DMEM 10% 1% NA NA 5% 
A375SM Human 
melanoma 












DMEM 10% 1% NA NA 10% 
C32 Human 
melanoma 











DMEM 10% 1% NA NA 10% 
MM-AN Human 
melanoma 
DMEM 10% 1% NA NA 10% 
HMVEC Primary human 
endothelial cell  
EGM2 NA 1% NA NA 5% 









aDefinition of terms: C3H3NaO3 = sodium pyruvate; CO2 = carbon dioxide; DMEM 
=  dulbecco’s modified eagle medium; EGM2 = endothelial basal medium; FBS = 
fetal bovine serum; GPS = glutamine penicillin-streptomycin; HMGS = human 
melanocyte growth supplement; NEAA = nonessential ammino acids; RPMI-1640 
= roswell park memorial institute 1640  
 
Casting the Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 Creation of western blot gels used specific formulas. The formulas and 
ratio of reagents depended on the resolving percentage that was needed to 
optimally view the protein of interest; the two percentages used in this project 
were 7.5% and 12%. The resolving portion of the gel is prepared first by mixing 
7.5 mL double distilled water (ddH2O), 3.75 mL resolving buffer (National 
Diagnostics), 3.75 mL ProtoGel 30% (National Diagnostics), 50 µL 10% 
ammonium persulfate (APS) and 10 µL of tetramethylethylenediamine (TEMED); 
those ratios are for the construction of two 7.5% resolving gels. This solution was 
pipetted into the cast for the gel and allowed to solidify for one hour. During this 
time the stacking portion of the gels was created by mixing 3.05 mL ddH2O, 1.25 
mL resolving buffer, 0.65 mL ProtoGel 30%, 25 µL 10% APS and 5 µL of 
TEMED; those ratios result in the construction of two 4% stacking gels. The 
stacking solution was pipetted into the gel cast and the comb was quickly placed 
in the gel; the stacking portion of the gel was allowed to solidify for one hour. For 
a 12% resolving gel the proportion of ddH2O to ProtoGel changed to 5.25 mL 





 In order to extract the proteins from cultured cells, the cells must be lysed 
and the proteins in the membranes solubilized using detergents. To begin the 
process the cell culture dish was removed from the incubator and placed on ice 
in order to prevent protein degradation. Following this the medium was removed 
via pipette from the dish. In order to wash the cells phosphate buffered saline 
(PBS, 1x, ph 7.2, ~5 mL) was added and swirled around the dish. Once the cells 
were appropriately washed the PBS was removed via pipette. A second PBS 
was performed in order to make sure the cells were as clean as possible. In 
order to begin the lyses of the cells between 100 microliters and 1 milliliter of cell 
lysing buffer consisting of radioimmunoprecipitation assay (RIPA) buffer (New 
England BioLabs) with a Complete mini protease inhibitor cocktail (Sigma 
Aldrich) was added to the dish. The amount of lysis buffer added depends on 
several factors such as the confluence of the cells in the dish as well as the size 
of the dish. In order to mechanically break open the cells as well as have them lift 
off of the plate a clean cell scrapper was used to scrap the dish. The total volume 
of liquid that was produced by both the lysis buffer and scrapping of the dish was 
pipetted into a microfuge tube and placed in ice for a minimum of one hour. To 
aid in the complete lysis of the cells intermittently the microfuge tube was 
vortexed (approximately every five to ten minutes). Once the hour had passed 
the whole cell lysate was centrifuged at 4 °C at 10,000 revolutions per minute 
(RPM) for ten minutes in order to separate the supernatant from the cellular 
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organelles. The supernatant containing the cellular proteins was pipetted into a 
new microfuge tube, this served as the protein lysate. The pellet that was left 
behind in the original microfuge tube was kept as a backup in case more lysate 
was needed. Both tubes were then placed into the -80 °C freezer for storage. 
Protein Assay 
 A protein assay is used to estimate the concentration of protein in a given 
sample by comparing to known samples of proteins. This Bio-Rad DC protein 
assay is based on the well-known Lowry Assay (Lowry, Rosebrough, Farr, & 
Randall, 1951) and can be used on proteins isolated using detergent 
solubilization. This assay has been modified from the manufacturer’s instructions 
to a 96 well format. Protein samples and stock bovine serum albumin (BSA, 10 
mg/mL) are thawed on ice. Using a 96 well plate, 25 µL of ddH2O was pipetted 
into all wells in column 4 except 4H. Following this 25 µL of BSA stock solution 
was pipetted into well 4G and 4H, after this well 4G was mixed well via pipetting 
up and down. In order to produce the correct dilutions 25 µL of the solution in 
well 4G was pipetted into well 4F. Well 4F was mixed thoroughly and then 25 µL 
of the solution in 4F was added to well 4E. This process of serial dilution was 
repeated well to well up until well 4B, meaning that well 4A contained only 
ddH2O. 5 µL of the BSA/ddH2O dilutions from each well in column 4 were 
pipetted to the three preceding wells (A-C) of that row; this was continued 
through well 4H. 5 µL of each unknown protein sample was pipetted to two wells 
after column 4, column 6 and 7, each new sample was pipetted into the row 
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below but still within columns 6 and 7. 1 mL of reagent A (Bio-Rad), and 20 µL of 
reagent S (Bio-Rad) were mixed in a microfuge tube and vortexed. After which 
25 µL of the reagent A/S solution was pipetted into all wells except column 4 
wells. 200 µL of reagent B (Bio-Rad) was added to all wells except column 4 
wells. With the addition of reagent B the samples should turn blue. A 
spectrophotometer was used in order to read the absorbance of each sample at 
650nm. The BSA standards as absorbance versus concentration of BSA in 
mg/mL were graphed. Via linear regression, the R2 and best-fit straight line were 
calculated. From the formula: y=mx +b, where m is the slope and b is the y 
intercept the protein concentration of all unknown samples were calculated.  
Western Blot 
 In order to observe relative protein amounts protein samples must be run 
on a western blot gel. In order to prepare the protein samples and molecular 
weight standards they must be thawed on ice. Once the samples and ladder 
were thawed, protein lysates (40 ug protein) were mixed with 6x SDS reducing 
sample buffer (Boston Bioproducts) and ddH2O to create a final volume of 48 µL 
that was loaded into the wells of the gel. Most western blot antibodies recognize 
denatured proteins and not naïve ones thus to help denature the proteins the 
samples were heated to 100 degrees °C for eight – ten minutes. Once the 
samples were heated for the appropriate time the microfuge tubes were removed 
from the heater and placed in ice. Using 1x running buffer (25mM Tris, 192mM 
glycine, 0.1% SDS, pH 8.3) (Boston Bioproducts) the running apparatus was 
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filled and then samples were slowly pipetted into the appropriate wells in the 
western blot gel. The lid, with the power supply imbedded in it, was placed onto 
of the running apparatus. The gel was run at 90 volts, 400 milliamps for two 
hours or until the blue line has ran all the way to the bottom of the gel. Once the 
gel has completed the appropriate run time, the transfer apparatus was 
assembled and filled with 1x transfer buffer (25mM Tris, 192mM glycine, pH 8.4) 
(Boston Bioproducts). The sponges, filter paper and membrane (nitrocellulose) 
were all presoaked in the transfer buffer. Before assembling the “sandwich” the 
stacking portion of the gel was cut off. The “sandwich” consists of the sponge, 
filter paper, gel, membrane, filter paper and sponge again. The gel was laid on 
the filter paper with the ladder on the right hand side at which point the 
membrane was placed over the gel. In order to ensure that no bubbles were 
present between the gel and the membrane a pipette was used to roll out all the 
bubbles before the last filter paper and sponge were placed in position and the 
“sandwich” was closed. The “sandwich” was placed in the transfer apparatus with 
the black side facing towards the middle of the transfer apparatus and the gel 
was transferred to the membrane at 500 volts, 300 milliamps for two hours. Once 
the transfer is complete, ponceau (Sigma) was poured onto the membrane as a 
quality control to make sure protein was transferred from the gel to the 
membrane. The ponceau was washed off with 1x Tris-Buffered Saline (TBS) (10 
mM Tris-HCl, 150 mM NaCl, pH 7.4). 5% non-fat dry milk (Bio-Rad) was made, 
via diluting 5 grams of non-fat dry milk in 100 mL Tris-Buffered Saline-(0.1%) 
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Tween (TBS-T). in order to prevent nonspecific binding the membrane was 
blocked in 5% milk for one hour. After the hour the milk was washed off by a brief 
was of the membrane with TBS-T. The membrane was incubated in the 
appropriate primary antibody that had been diluted to a concentration of 1:1000 
using TBS-T and left to incubate overnight in 4 °C. The following day the primary 
antibody was washed off using TBS-T in a three wash manner each of which 
lasted 15 minutes. Once the 3x15 minute washes had concluded the membrane 
was incubated in the appropriate secondary antibody that has been diluted to a 
concentration of 1:3000 using TBS-T for one hour at room temperature on the 
tilter on low/medium speed. After the one-hour had passed the secondary 
antibody was washed off in the same manner as the primary antibody. After the 
post secondary antibody TBS-T washes the membrane was incubated in a 
solution made up of a 1:1 ration of Oxidizing Reagent and Enhanced Luminol 
Reagent that formed an enhanced chemiluminescence (ECL) solution (Bio-Rad), 
for five minutes on the tilter on low/medium speed during which the container 
with the membrane in it was wrapped in aluminum foil. After the five minutes had 
pasted the membrane was removed and placed between two transparent sheets 
and slowly wiped across the top transparent paper to remove any bubbles. At 
this time the membrane was placed in side the the Bio-Rad ChemiDoc Touch 





B16F10 Dose Response to Sema3F 
 In order to observe the effect that Sema3F has on B16F10 cells PD-L1 
levels in vitro and in a dosage dependent manner a dose response was 
performed. First B16F10 cells were trypsonized and counted using a 
hemocytometer. Cells were then diluted to the concentration that was desired to 
plate for the dose response. B16F10 cells were then plated using completed 
media consisting of DMEM, 10% FBS and 1% GPS. The cells were either 
incubated in serum positive or serum negative medium. Serum positive medium 
contains FBS where as the serum negative does not. In the case of the serum 
negative incubated cells the cells were plated with the serum positive and then 
24 hours later that medium was removed and serum negative medium was 
added. The cells were allowed to seed for 24 hours after which they were treated 
with different dosages of Sema3F (100, 200, 400, 600, 800 ng/mL). This was 
done by pipetting off the media and replacing it with Sema3F media. The cells 
were allowed to incubate for 48 hours before being lysed. The cells were allowed 
to incubate in the Sema3F for 48 hours due to the fact that Li et al., 2016 detailed 
that the half-life of PD-L1 was dependent upon specific posttranslational 
modifications such as glycosylation and phosphorylation. The longest half-life 
was approximately 18 hours, thus the 48 hours allowed us to see the impact of 





Quantification of Western Blot Band by Pixels Using ImageJ 
 When looking at protein expression level differences of the same protein 
that were subjected to differing conditions it is helpful to quantify the pixilation of 
the western blot bands. This is done by exporting the image from Image Lab and 
then saving it as a Tif. The Tif was then opened in ImageJ. Once the Tif was 
opened in ImageJ a rectangle was drawn around the ladder and samples, which 
was then cropped via Command, Shift X. In order to subtract the background the 
“Process” function was clicked followed by clicking “subtract background”, 
selecting anywhere between 50-80 pixels. Once the background had been 
subtracted another rectangle was drawn over the first band, with the higher being 
better, at which point “Command 1” was pressed. The recently drawn rectangle 
was copied and dragged over to the second band and “Command 2” was 
pressed, this was repeated this for the rest of the bands. Once the last band was 
encountered, instead of the “Command 2” sequence, “Command 3” was pressed, 
resulting in a histogram. Via the “straight line” feature a line was drawn from the 
inflection point on one side to the inflection point on the other side. The “Magic 
Wand” feature was used to calculate the area under the curve by simply clicking 
with the “Magic Wand” underneath the curve. This was repeated for all the 
bands. At this point the results were copied and pasted into an excel 
spreadsheet. After doing this was completed for the “Protein of Interest” all the 
steps were repeated for the “Loading Control”. After this has been done for the 
“Loading Control” and the values had been copied and pasted into the same 
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excel spreadsheet the ratio of Protein of Interest/Loading Control was calculated. 
In order to normalize the ratios to the control the Ratio of Band/Ratio of Control 
was calculated. This in turn gave you the “Quantified Strength of Band 
Compared” to “Loading Control”. 
Viability Assay 
 When looking at the effect that Sema3F has on both primary murine 
melanocytes as well as murine melanoma cells a viability assay is a helpful 
assay to perform. The specific cells (Mela C and B16F10) were tryposinized and 
counted via hemocytometer. Cells were then diluted to the concentration that 
was desired to plate for the viability assay. The cells were then plated using the 
appropriate media. 24 hours later the media was removed via a vacuum attached 
to a flask. Fresh media with differing dosages of Sema3F (75, 150, 300, 600, 
1200 ng/mL) was pipetted back on to the cells. The cells were allowed to 
incubate in the Sema3F media for 72 hours. After the total of 96 hours CellTiter 
96 AQueous One Solution Cell Proliferation Assay ([3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS]) 
(Promega) was added to the cells in each well at a concentration of 20 µL of 
MTS per 100 µL of media. The cells were allowed to incubate at 37 °C at 5% 
CO2 for 1-4 hours before reading the absorbance at 490nm using a 
spectrophotometer. On an excel spreadsheet the average absorbance for every 
Sema3F dosage including the control was calculated. From the averages for 
each absorbance a standard deviation was calculated for each dosage and the 
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control. From the standard deviations a standard error was calculated. A graph of 
absorbance vs. dose of Sema3F with error bars based off of the standard 
deviations was created. 
Immunohistochemistry Staining: CD4, Paraffin Section 
 The formalin-fixed, paraffin-embedded (FFPE) tissue section slides were 
placed on the slide warmer at 60°C in order to evaporate the water between the 
tissue and the slide. Once the water had been evaporated the sections were de-
paraffinize and rehydrated via four minutes and then three minutes in xylene, two 
times for two minutes each in 100% ethanol, two times for two minutes each in 
95% ethanol, two minutes in 70% ethanol, two minutes in 50% ethanol and finally 
five minutes in 1x PBS. Antigen retrieval using Tris EDTA at a pH of 9 was 
performed so as to better expose the epitope for the appropriate antibody. 
Pouring Tris EDTA into a coplin jar and allowing it to boil for 10 minutes in the 
microwave before allowing the sections to cool for 30 minutes at room 
temperature accomplished the necessary antigen retrieval for the specific 
antibody being used. After the antigen retrieval the sections were washed with 1x 
PBS for three times for three minutes each time. In order to prevent endogenous 
peroxidases from reacting with the secondary antibody a blocking step using 3% 
H2O2 in MeOH for 12 min was performed, the 3% H2O2 in MeOH was prepared 
fresh. Again the sections were washed with 1x PBS for three times for three 
minutes each. So as to prevent nonspecific binding the sections were incubated 
in TNB for 30 minutes at room temperature as a blocking step. The rabbit anti-
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CD4 (abcam) (primary antibody 1:1000) was diluted in TNB (blocking buffer) and 
the sections were incubated at 4°C overnight. The next day the slides were 
washed in 1x PBS for three times for three minutes each. After which the 
secondary antibody, biotinylated anti-rabbit (Vector) (1:200), which was diluted in 
TNB (blocking buffer) was added onto the sections for one hour at room 
temperature. After the one-hour had expired the sections were washed in 1x PBS 
for three times for three minutes each. During the secondary antibody incubation 
period the Vectastatin Elite ABC Kit was prepared at least 30 minutes prior to its 
use. After the post secondary antibody 1x PBS washed the Vectastatin Elite ABC 
Kit was added to the sections for 30 minutes at room temperature. Once the 30 
minutes has pasted the slides were washed in 1x PBS for three times for three 
minutes each. At this point the slides with treated with ImmPACT DAB 
Peroxidase Substrate Kit for an appropriate amount of time until the desired cells 
turned brown. In order to stop the DAB reaction the slides were washed with 
H2O. After which the slides were counter stained with haematoxylin. Once the 
desired counterstain had been achieved the haematoxylin reaction was stopped 
using H2O. At this time a second counter staining was performed using Tacha’s 
Bluing Solution. Once the desired amount of counter stain has been achieved the 
Tacha’s Bluing Solution reaction was stopped using H2O. The slides were placed 
on a drying rack overnight. The next day using permount and xylene the slides 




Sema3F and VEGF Are Present in the Epidermis but VEGFR2 Is Not 
 In order to investigate the possible function of Sema3F, VEGF, and 
VEGFR2 in the epidermis, the presence of these proteins was determined in 
mouse epidermal sections using different techniques. Figure 10 shows the 
results of these staining experiments on sections from wild-type (WT) C57B1/6 
mice. Prior Bielenberg Laboratory members contributed these data to the study. 
 In Figure 10A-C, sections of LacZ mice were utilized to visualize the 
presence of VEGF or VEGFR2 in the epidermis. For VEGF, the mouse had one 
VEGF allele replaced with a LacZ allele, creating VEGF+/LacZ, and for VEGFR2, 
the mouse had one VEGFR2 allele replaced with a LacZ allele, creating 
VEGFR2+/LacZ. After these sections were stained, the appearance of a blue color 
indicated the presence of a VEGF promotor (VEGF+/LacZ) or a VEGFR2 promotor 
(VEGFR2+/LacZ), which in either case had turned on the LacZ gene. The image in 
Figure 10A shows blue staining (arrows) in the epidermis and supports a positive 
test for VEGF. The images in Figure 10B-C, however, show a lack of blue 
staining (arrows) in the epidermis and support a negative test for VEGFR2. 
Overall, the results demonstrated the presence of VEGF and the absence of 
VEGFR2 in the murine epidermis. 
 In Figure 10D, an FFPE section of WT mouse epidermis was processed 
by IHC staining with a specific antibody to Sema3F. The image shows intense 
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Figure 10. Visualization of the specific localization of Sema3F, VEGF, and 
VEGFR2 in murine epidermal tissue sections. (A) VEGF+/LacZ mouse 
demonstrates the presence of VEGF in the epidermis. Arrows point to blue 
staining in the upper layer. (B, C) VEGFR2+/LacZ mouse demonstrates the lack of 
VEGFR2 in the epidermis. Arrows point to upper layer which exhibits no blue 
staining. (D) Sema3F IHC staining of WT mouse epidermis demonstrates the 
presence of Sema3F in the epidermis. LacZ = bacterial beta-galactosidase gene; 
VEGF = vascular endothelial growth factor; VEGFR2 = vascular endothelial 
growth factor receptor 2 ; Sema3F = semaphorin 3F (murine). Taken from 




Melanocytes Express NRP2/Nrp2 
 In order to determine if any VEGF receptors are present in the epidermis 
western blot analysis was conducted. Figure 11A-B demonstrates that both 
murine and human melanocytes express Nrp2/NRP2. This information when 
taken in conjunction with figure 10A-C exhibits that melanocytes express the only 
VEGF receptor in the epidermis. This displays a lack of an ability to transduce a 
VEGF signal within the epidermis. Murine Nrp2 expression was detected through 
the use of Cell Signaling Technology Nrp2 (D39A5) rabbit polyclonal antibody.  
 Human NRP2 expression was detected through the use of Santa Cruz NRP2 
antibody. Prior Bielenberg Laboratory members contributed these data to the 
study. 
 
Figure 11. Murine and human melanocytes express Nrp2/NRP2. (A) A 
western blot of cells found within murine skin demonstrates Nrp2 expression on 
murine melanocytes. (B) A western blot of cells found within human skin 
demonstrates NRP2 expression on human melanocytes. Nrp2/NRP2 = neuropilin 
2 (murine/human); Mk Hi = primary murine keritinocytes; NIH 3T3 = transformed 
murine fibroblasts; Mela C = primary murine melanocytes; B16F10 = murine 
melanoma; HaCat = human keritinocytes; Milo = human fibroblasts; HeMn = 
human epidermal melanocytes (neonate); PAE KDR = porcine aortic endothelial 
transformed with vascular endothelial growth factor receptor 2; PAE NRP2 = 
porcine aortic endothelial transformed with neuropilin 2. Unpublished; contributed 





Human Melanocytes and Melanoma Do Not Express VEGFR2 
 As demonstrated by western blot in figure 11A-B, both human and murine 
melanocytes express NRP2/Nrp2. In order examine the potential ability of VEGF 
to signal in an autocrine manner on human melanocytes and melanoma via 
NRP2:VEGFR2 dimerization western blot analysis was performed. Figure 12A 
demonstrates that human melanocytes express NRP2, while additionally 
exhibiting that human melanomas express NRP2 as well. Figure 12B reveals that 
neither human melanocytes nor human melanocytes express VEGFR2 when 
compared to the control of PAE KDR. This demonstrates that NRP2 binding of 
VEGF must serve a different purpose then signal transduction. Prior Bielenberg 


















Figure 12. Human melanocytes and melanomas express NRP2 but not 
VEGFR2. (A) A western blot of human melanocytes and melanomas 
demonstrates the presence of NRP2. (B) A western blot of human melanocytes 
and melanomas demonstrates the lack of VEGFR2. NRP2 = neuropilin 2 
(human); VEGFR2 = vascular endothelial growth factor receptor 2; A2058 = 
human melanoma; A375SM = human melanoma; MMAN = human melanoma; 
WM 226-4 met = human melanoma metastases; HeMn = human epidermal 
melanocytes (neonate); PAE KDR = porcine aortic endothelial transformed with 
vascular endothelial growth factor receptor 2; PAE NRP2 = porcine aortic 
endothelial transformed with neuropilin 2 (human). Unpublished; contributed by 






B16F10 in Nrp2 KO Mice Do Not Grow 
 In a further attempt to elucidate the impact Nrp2 has on murine melanoma 
(B16F10) growth B16F10 was injected into five Nrp2 WT mice and five Nrp2 KO 
mice. Both groups of mice were terminated 17 days after injection. The Nrp2 WT 
mice average tumor volume increased throughout the trial to an average tumor 
volume of 800 mm3 on day 17. The Nrp2 KO mice results were polar opposite. 
Figure 13 demonstrates that the tumors did not grow as evidenced by an 
average final tumor volume of 50 mm3 17 days post injection. These data 
suggests that host Nrp2 may be required for B16F10 growth. Prior Bielenberg 
Laboratory members contributed these data to the study.  
 
Figure 13. Nrp2 KO mice do not support B16F10 growth compared to WT 
mice. B16F10 is injected into both WT and control mice. Seventeen days after 
injection, Nrp2 WT mice show an increase in tumor volume of 800 mm3, whereas 
Nrp2 KO mice show essentially no growth in tumor volume.  Nrp2 = neuropilin 2 
(murine); B16F10 = murine melanoma; VEGF-C = vascular endothelial growth 






SEMA3F Inhibits Migration of Mela C and B16F10 
 Since it has been established in previous studies such as Bielenberg et 
al., 2004 and in figures 11A-B and 12A that NRP2/Nrp2 is present in both 
melanocytes and melanoma the functionality of the NRP2/Nrp2 must be 
examined; the migration assay serves this function. In a publication by Kessler et 
al., 2004 it was exhibited that SEMA3F inhibits EC migration thus demonstrating 
that NRP2 remains functional on EC as well as proving that SEMA3F has the 
ability to inhibit cell migration. In figure 14A-B it was observed that SEMA3F 
inhibited migration of both Mela C and B16F10 thus demonstrating that in 
addition to NRP2 being functional on EC, NRP2/Nrp2 remains functional in 
melanocytes and cancerous cells, melanoma. Mela C was plated at a density of 
40,000 cells per well, and B16F10 was plated at a density of 20,000 cells per 
well. Both were plated into four groups (control, 0 ng/mL, 150 ng/mL, 300 ng/mL, 
and 600 ng/mL) and allowed to incubate with the Sema3F for 16 hours. The 
results in Figure 14A-B demonstrated that both Mela C and B16F10 migrations 
were significantly reduced in the presence of increasing doses of Sema3F. Prior 













Figure 14. Murine melanocyte and melanoma migration in vitro is inhibited 
by SEMA3F. (A) Murine melanocyte migration is inhibited by SEMA3F at 
dosages of 150, 300, and 600 ng/mL. (B) Murine melanoma migration is inhibited 
by SEMA3F at dosages of 150, 300, and 600 ng/mL. B16F10 = murine 
melanoma; MelaC = primary murine melanocyte; SEMA3F = semaphorin 3F. 






Sema3F Does Not Inhibit Mela C or B16F10 Viability but Does Inhibit EC 
Viability  
 As shown in figure 14A-B, Kessler et al., 2004 and Bielenberg et al., 2004 
NRP2/Nrp2 is a functionally receptor for SEMA3F/Sema3F through the inhibition 
of migration for EC, Mela C, B16F10, A375SM and associated clones. Therefore 
in order to observe the effect of Sema3F on Mela C and B16F10 viability an MTS 
assay was performed. This specific type of assay does not measure cell 
proliferation but instead cell viability. Viability is defined as a metabolically active 
cell. In the MTS assay the method for determining if a cell is metabolically active 
is by treating the cells with a MTS compound. If a cell is metabolically active the 
MTS compound is reduced into a colored formazan, which provides an 
absorbance signal at 490nm. The results of the MTS assay displayed in figure 
15A-B exhibited that in the case of both Mela C and B16F10 Sema3F did not 
affect cell viability. This is in contrast to the results seen in figure 15C where LEC 
and HMVEC, both of which where shown to have their proliferation inhibited by 
Sema3F/SEMA3F (the LEC and HMVEC proliferation assay’s were completed by 
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Figure 15. Murine melanocyte and melanoma viability in vitro is unaffected 
by Sema3F. (A) Murine melanocyte (Mela C) viability is unaffected by Sema3F 
over a dosage range of 0-1200 ng/mL. (B) Murine melanoma (B16F10) viability is 
unaffected by Sema3F over a dosage range of 0-1200 ng/mL. (C) LEC and 
HMVEC viabilities are diminished when treated with SEMA3F over a dosage 
range of 0-1300 ng/mL. Mela C = primary murine melanocytes; B16F10 = murine 
melanoma; HMVEC = human microvasculature endothelial cell; LEC = lymphatic 
endothelial cell; Sema3f = semaphorin 3F (murine); SEMA3F = semaphorin3F 
(human). Figure C is unpublished; contributed by (D. Bielenberg, 2018). 
 
SEMA3F Dephosphorylates pAKT in Human Melanocytes 
 As demonstrated in figure 14A-B Sema3F inhibits melanocyte and 
melanoma migration. In an attempt to elucidate the mechanism behind this HeMn 
was treated with SEMA3F for 30 minutes at increasing dosages to observe its 
effect on pAKT. Western blot analyses revealed that with increasing dosage of 
SEMA3F increasing amounts of pAKT were dephosphorylated while total AKT 
remained constant. Prior Klagsbrun Laboratory members contributed these data 
to the study. 
 
Figure 16. SEMA3F functions to dephosphorylate pAKT in human 
melanocytes. Human melanocyte (HeMn) pAKT is dephosphorylated by 
SEMA3F in a dosage dependent manner. HeMn = human melanocyte (neonate) 
pAKT = phosphorylated protein kinase B (detected at the serine 473 residue); 
AKT = protein kinase B; pS6K = phosphorylated ribosomal S6 kinase; S6K = 
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ribosomal S6 kinase; SEMA3F = semaphorin 3F (human). Adapted from 
(Nakayama et al., 2015). 
 
Sema3F Increases PD-L1 Expression on B16F10 In Vitro 
 In an effort to understand the impact of Sema3F on PD-L1 expression in 
B16F10 a dose response test was conducted, the results of which are displayed 
in figure 16. Quantification of the pixilation of the protein of interest (PD-L1) 
normalized to its beta actin pixilation and compared to the control revealed a 10.5 
fold increase in PD-L1 levels at a dosage of 200ng/mL of Sema3F. The lanes 
went in order of increasing Sema3F dosage with the final lane being the control 
(no treatment with Sema3F). 
  
 
Figure 16. Sema3F increases PD-L1 expression in B16F10 murine 
melanoma model in vitro. These western blots demonstrate that when B16F10 
is treated with Sema3F, the B16F10 PD-L1 levels increase compared with no 
treatment. The largest fold increase is seen with a dosage of 200 ng/mL (10.5-
fold increase). B16F10 = murine melanoma; Sema3F = semaphorin3F (murine); 
PD-L1 = programmed death ligand-1. 
 
Sema3F Impacts CD4 Tumor Infiltration in B16F10 In Vivo 
 In order to explore the in vivo affects of Sema3F on infiltration of CD4 





pump in WT mice injected with B16F10. The Sema3F pump released 0.05 mg/kg 
of Sema3F daily. The Sema3F was stained using a concentration of 1:1000 
whereas the PBS pump a concentration of 1:500. It was noted in the Sema3F 
pump staining that the DAB was darker around the cell, indicating it was binding 
to a cell surface marker. This made sense because CD4 is a cell surface marker. 
In figure 17A-B there appeared to be a slight increase in CD4 infiltration in the 
Sema3F pump sections when compared to the PBS pump sections. In figure 17B 
a fair amount of background staining is present and cannot be considered as 
CD4 positive. The IHC staining of a FFPE spleen tissue section in figure 17C 





















Figure 17. CD4 infiltration into B16F10 murine melanoma tumors is 
impacted by Sema3F slow release via a mini osmotic pump. The images are 
examining CD4 infiltration through IHC staining between a B16F10 tumor treated 
with Sema3F via mini osmotic pump, B16F10 tumor treated with PBS via mini 
osmotic pump and a normal spleen tissue section. (A) Sema3F pump (1:1000) 
increases the appearance of CD4 cell surface expressing cells infiltration within 
the B16F10 tumor microenvironment (picture taken at 200x magnification). (B) 
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PBS pump (1:500) impact on the tumor infiltration of CD4 cell surface expressing 
cells within the B16F10 tumor microenvironment (picture taken at 200x 
magnification). (C) A spleen (1:500) stained for CD4 expressing cells, used as a 
positive control (picture taken at 200x magnification). The arrows point to the 
CD4 positive cells. CD4 = cluster of differentiation 4; B16F10 = murine 
























 The basis for this study was derived from several sources. The initial 
investigation of the NRP2 role in melanocytes and melanoma was a continuation 
of the work of a former Boston University School of Medicine master’s student, 
Salvatore Rizzo, in the Bielenberg Laboratory at Boston Children’s Hospital 
(Rizzo, 2015). The idea to examine the ability of SEMA3F to affect PD-L1 levels 
originated from the results of collaborative work in this same laboratory with T-
cells and organ transplantation in mice (unpublished data). 
 As shown in figure 14A-B, and demonstrated in Kessler et al., 2004 and 
Bielenberg et al., 2004 NRP2/Nrp2 is a functionally receptor for 
SEMA3F/Sema3F through the inhibition of migration for EC, Mela C, B16F10 and 
A375SM and associated clones. In addition to observing the effects of SEMA3F 
on migration it was demonstrated by Kessler et al., 2004 that SEMA3F also has 
the ability to inhibit EC proliferation. Bielenberg et al., 2004 exhibited that 
whereas SEMA3F has the ability to inhibit melanoma, A375SM and associated 
clones, migration that SEMA3F does not impact their proliferation. In figure 15A-
C it was observed that the effect of Sema3F on the proliferation/viability of 
primary murine melanocytes proliferation more closely resembles that of EC or 
melanoma. A potential mechanistic explanation for this resides in a paper by 
Nakayama et al., 2015, which demonstrated that when HeMn were treated with 
increasing dosages of SEMA3F pAKT was reduced. AKT is an important 
signaling molecule in both migration and survival thus with SEMA3F reducing the 
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amount of pAKT in human melanocytes it understandable how cell migration is 
inhibited. 
 Since NRP2 was initially discovered in neurons (Chen et al., 1998), it 
follows logic that melanocytes express NRP2 because they are NCC-derived 
(Cichorek et al., 2013) and must migrate to their final location with assistance 
from the repulsion of SEMA. This would lead one to postulate that the 
combination of SEMA3F in the epidermis and SEMA receptors (NRP1/2 and 
plexin) on the surface of the melanocytes could function to confine epidermal 
melanocytes to the stratum basale of the epidermis. A necessary step in 
confirming this hypothesis would be the IHC staining of melanocytes in WT, 
inducible SEMA3F KO, and constitutive SEMA3F KO mice. If SEMA were 
present in the epidermis to maintain the basal melanocyte location, this finding 
could provide a rationale for the reason why SEMA3F is downregulated in highly 
metastatic malignancies (Bielenberg et al., 2004). Decreasing a protein that 
functions to restrict movement would be conducive to metastasis. 
 In the examination of melanomas, the combination of the presence of 
NRP2 and the absence of VEGFR2 on the melanoma cell surface, together with 
the absence of any VEGFR2 in the epidermis, is intriguing for many reasons. 
First of all, the lack of VEGFR2 would indicate that the VEGF present is not 
participating in signal transduction. In the absence of VEGFR, the binding of 
VEGF and NRP2 does not induce a signaling cascade. Secondly, the high 
concentration of VEGF found in the epidermis would raise a question about its 
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purpose in the absence of VEGFR2. An interesting hypothesis as to the function 
of the NRP2:VEGF binding is that this complex has the potential to serve as a 
depot to create a strong proangiogenic chemogradient for tumor-associated 
angiogenesis (Figure 17). Of course, this would be dependent on NRP2 
sequestering the VEGF at the cell surface and not internalizing it. This theory 
could be tested by treating melanoma cells with fluorescently tagged VEGF-A/-C 
and observing the location of the fluorescent signal. 
 
 
Figure 18. Melanoma and the NRP2 depot theory. Melanoma expresses high 
levels of NRP2 but lacks VEGFR2; thus, the NRP2 binding of VEGF potentially 
serves as a chemogradient depot to promote tumor-associated angiogenesis. 
NRP2 = neuropilin 2 (human); VEGF = vascular endothelial growth factor; 
VEGFR = vascular endothelial growth factor receptor. Unpublished; contributed 
by (D. Bielenberg, 2018). 
 
 If it is found that VEGF bound to NRP2 is indeed maintained at the cell 
surface, the result would strengthen an argument for targeting NRP2 in cancer 
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therapies as well as treating patients with SEMA3F. The presence of SEMA3F 
would competitively inhibit not only VEGF but also other growth factors, such as 
PGF and hepatocyte growth factor (HGF), from binding NRP2. 
 Immunotherapy has changed the treatment strategy for many 
malignancies, including melanoma. However, obstacles still exist, and one of 
these problems is how to increase the tumor-infiltrating lymphocytes (TILs). If the 
treated lymphocytes are unable to gain access to the tumor, they cannot have an 
effect on the mutated cells. Recent efforts to increase TILs have included 
increasing PD-L1 levels. This potential treatment must coincide with an 
immunotherapeutic; otherwise, the treatment would aid the cancer in hiding from 
the immune system.  
 Bielenberg et al. (2004) demonstrated that SEMA3F inhibited tumor-
associated angiogenesis in melanoma. Instead of complete inhibition of 
angiogenesis, this action may prune and/or normalize the tumor blood vessels. 
Tumor blood vessels are known to be poorly formed, leaky, and immature (Goel, 
Wong, & Jain, 2012). The process of pruning or normalizing the tumor vessels 
could increase the number of TILs through the effect of SEMA3F on the tumor 
cells. Another potential benefit of the SEMA3F-induced normalization of the 
tumor blood vessels is that the perfusion of the tumor would aid in decreasing 
hypoxia-inducible factor-1 alpha (HIF1-α) levels. HIF1-α not only stimulates 
VEGF secretion (Liu et al., 2008) but also has been shown to downregulate 
NRP2 in the human melanoma cell lines MM-AN and WM-226-4 (Coma, 
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Shimizu, & Klagsbrun, 2011). These interactions could be problematic, because 
in order  for SEMA3F to signal, it must bind NRP2 before dimerizing with plexin 
A1. A necessary step to evaluate the ability of SEMA3F to normalize the tumor 
blood vessels would be to perform IHC staining for pericytes. These cells are 
considered a key component of normalized blood vessels when compared with 
tumor-associated angiogenic-derived blood vessels, which lack pericytes (Goel 
et al., 2012). In addition, a perfusion assay could be conducted to observe the 
perfusion level of the tumor. Finally, performing a western blot with lysates from 
both SEMA3F- and PBS-treated tumors and evaluating the observed expression 
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